Disease Domain | Count |
---|---|
Infectious Diseases | 2 |
Neoplasms | 1 |
Top 5 Drug Type | Count |
---|---|
DNA vaccine | 2 |
Oligonucleotide | 1 |
Top 5 Target | Count |
---|---|
TLR9(Toll like receptor 9) | 1 |
Target |
Mechanism TLR9 agonists [+1] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhasePhase 1 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
Mechanism- |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
Mechanism- |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date01 Aug 2020 |
Sponsor / Collaborator |
Start Date11 May 2016 |
Sponsor / Collaborator |
Start Date01 Sep 2014 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Lefitolimod ( TLR9 ) | Colorectal Cancer More | Phase 3 |
MGN-1333 | Hepatitis B More | Preclinical |
MGN-1331 | Leishmaniasis More | Preclinical |
MGN-1404 ( TNF-α ) | Melanoma More | Discontinued |
Lymphoma gene therapy(MOLOGEN AG) | Lymphoma More | Discontinued |